ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08535
0,00%
Bitcoin
68.960,80
-0,44%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Cel Sci Corporation New (CVM)

  7. Cel Sci Corporation New (CVM) News

CVM

Cel Sci (CVM)

Cel Sci Corporation New
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:CVM
DatumZeitQuelleÜberschriftSymbolFirma
16/05/202415h00Business WireCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
15/05/202422h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:CVMCel Sci Corporation New
10/05/202415h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
09/05/202419h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
09/05/202415h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
08/05/202415h00Business WireCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerAMEX:CVMCel Sci Corporation New
23/04/202415h00Business WireCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsAMEX:CVMCel Sci Corporation New
19/03/202414h00Business WireCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyAMEX:CVMCel Sci Corporation New
07/03/202417h33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:CVMCel Sci Corporation New
07/03/202417h33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:CVMCel Sci Corporation New
07/03/202417h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:CVMCel Sci Corporation New
06/03/202414h45Business WireCEL-SCI Corporation Issues Letter to ShareholdersAMEX:CVMCel Sci Corporation New
15/02/202414h00Business WireCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
14/02/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:CVMCel Sci Corporation New
13/02/202418h00Business WireCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
09/02/202414h44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
09/02/202414h30Business WireCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
06/02/202415h00Business WireCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugAMEX:CVMCel Sci Corporation New
31/01/202415h00Business WireEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®AMEX:CVMCel Sci Corporation New
02/01/202415h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202415h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202415h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
22/12/202322h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:CVMCel Sci Corporation New
22/12/202314h00Business WireCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsAMEX:CVMCel Sci Corporation New
21/12/202322h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:CVMCel Sci Corporation New
04/12/202314h30Business WireUK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck CancerAMEX:CVMCel Sci Corporation New
20/11/202323h25Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
20/11/202322h15Business WireCEL-SCI Announces Closing of $5 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
16/11/202314h39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
16/11/202314h30Business WireCEL-SCI Announces Pricing of $5 Million Offering of Common StockAMEX:CVMCel Sci Corporation New
 Showing the most relevant articles for your search:AMEX:CVM

Kürzlich von Ihnen besucht

BIT
P1W3V5
NLBNPIT1W3V5 20991231 48...
BIT
UV8CWT
UniCredit Bank
UNSW3
KARSAETH
Karsasoft Token
NYSE
FEAC
Flying Eagle Acquisition
BIT
P20151
NLBNPIT20151 20991231 14...
NASDAQ
FOXWHX
Financials Select Portfo...
BOV
T1AM34R
Atlassian
AMEX
BBVX
LATK
NKNUSDT
NKN [Ethereum]
COIN
H2OOOOETH
H2O
POLO
BURGERUSDT
Burger Swap
EU
SGG2P
Euronext G Societe Gener...
LATK
HNTUSDT
Helium
EU
3795T
3795T
NASDAQ
ABIO
ARCA Biopharma
TG
CEK
Ceotronics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten